These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 16110026)

  • 1. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
    Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
    J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal gammopathy of undetermined significance.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2006 Sep; 134(6):573-89. PubMed ID: 16938117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.
    Rendtlew Danielsen JM; Knudsen LM; Dahl IM; Lodahl M; Rasmussen T
    Br J Haematol; 2007 Sep; 138(6):756-60. PubMed ID: 17760807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
    Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
    Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O; Heider U; Zavrski I; Possinger K
    Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
    Rossi F; Petrucci MT; Guffanti A; Marcheselli L; Rossi D; Callea V; Vincenzo F; De Muro M; Baraldi A; Villani O; Musto P; Bacigalupo A; Gaidano G; Avvisati G; Goldaniga M; Depaoli L; Baldini L
    Clin Cancer Res; 2009 Jul; 15(13):4439-45. PubMed ID: 19509142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
    N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.
    Girlanda S; Fortis C; Belloni D; Ferrero E; Ticozzi P; Sciorati C; Tresoldi M; Vicari A; Spies T; Groh V; Caligaris-Cappio F; Ferrarini M
    Cancer Res; 2005 Aug; 65(16):7502-8. PubMed ID: 16103105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
    Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
    Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
    Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
    Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
    Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
    Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
    Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.